Last update: Dec. 8, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Long-acting agonist of the glucagon-like peptide receptor type 1 (GLP-1) that stimulates the endogenous secretion of insulin and decreases that of glucagon.
Used in type 2 diabetes in combination with other oral anti-diabetics, especially metformin.
Subcutaneous administration once a week.
There is risk of hypoglycaemia even in monotherapy.
Since the last update, we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (very high molecular weight) make it very unlikely that it will be transferred to milk in significant quantities (Serrano 2014).
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil (Serrano 2014), except in premature babies and immediate neonatal period when there may be greater intestinal permeability.
Diet, exercise and breastfeeding improve blood glucose levels.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM